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Implementation of the prevention of mothef-to-child transmission 
of HIV programme in Zimbabwe: achievements and challenges
FTARWIREYI
Abstract
Recent scientific developments have led to feasible and effective interventions to reduce the risk of mother 
to child transmission of HIV. Even in resource poor countries, PMTCT programmes are being articulated as 
a priority in the national strategic frameworks. Thus PMTCT programmes are moving from being pilot 
projects to national programmes comprehensively integrated into other reproductive health programmes or 
HIV and AIDS prevention, care and support programmes.1
In Zimbabwe the prevention of mother-to-child transmission (PMTCT) of HIV infection has become an 
important national task. The 2001 national survey of HIV prevalence among women attending antenatal care 
revealed that 29.5% of the women were HIV positive.2 While an effective PMTCT programme using 
nevirapine can reduce the rate of this transmission by 50%,2 the Zimbabwe PMTCT National Expansion 
Programme has had its share of achievements and challenges since its launch in 2002.
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Introduction
HIV transmission from mother to child remains the second 
most common mode of HIV transmission in sub Saharan 
Africa after heterosexual transmission.3
Efforts to reduce this transmission have seen the 
implementation of the PMTCT National Expansion 
Programme in Zimbabwe, in 2002. Provinces were asked 
to step up their coverage and have at least 50% of their 
district hospitals implementing PMTCT activities by the 
end of 2002.4
The PMTCT national expansion programme is guided 
by a protocol of planned activities that involve:
1. Community social advocacy and mobilization for the 
programme at all levels.
2. Group information about PMTCT to pregnant women 
attending antenatal care.
3. Voluntary counselling to willing mothers (pre and 
post counselling).
4. Conducting HIV rapid testing.
5. Administration ofnevirapine to HIV positive women.
6. Modifying obstetric procedures when delivering HIV 
positive women.
7. Administration of nevirapine to babies born to HIV 
positive women.
8. Follow up of mother and baby pairs.2
This paper reviews the achievements and challenges 
met in the various stages of the Zimbabwe PMTCT National 
Expansion Programme.
Achievements.
Resource mobilization.
The Ministry of Health and Child Welfare opened doors 
to both international and local donors for financial and 
technical support of the national PMTCT Expansion 
programme. Among the donors who responded to this 
request were WHO, UNAIDS, CDC, KAPNEK 
CHARITABLE TRUST, UNICEF, ISPED, CESVI, 
COSV, ZVITAMBO, ZAPP, NAC and Hope Humana.4 
. Expansion work for the PMTCT National Expansion 
Programme started at the beginning of 2002. A national 
team responsible for the active coordination of the various 
PMTCT activities was put in place in the AIDS and TB 
Unit. This team, being funded by KAPNEK 
CHARITABLE TRUST, strengthened the single 
coordinator who had beforehand attempted to coordinate 
this complex national task.
At provincial level, PMTCT focal persons were identified 
and put in place. In some districts, PMTCT district site 
managers were also placed. In some PMTCT sites both 
health and non health cadres were hired with support from 
donorpartners to participate in various PMTCT activities.4
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By the end of 2002, out of the 59 districts in Zimbabwe, 
32 (54%) had registered for PMTCT and out of a total of 
1 370 maternity offering institutions, 952 (69.5%) had 
registered for PMTCT.4
Community social advocacy and mobilization fo r  the 
programme at all levels.
With funding from different donors, the districts that had 
registered for PMTCT implemented community and social 
advocacy and mobilization activities. It was needful that 
this activity had to be done. Expected behaviors and 
programme activities had to be explained to communities. 
Further more, in order to increase client participation, 
clients’ myths and misconceptions had to be cleared first.5
Community and social mobilization effectively helps to 
assess community problems, perceptions and needs that 
are likely to impinge on the success of the programme. 
Failure to involve the community at the start of a programme, 
results in an unsuccessful intervention, as the community 
may not know how to participate.6
However, while the noble idea of community social 
advocacy and mobilization was carried out, information, 
education and communication materials where not made 
available to many districts. Matebeleland North was the 
only province that produced its own PMTCT materials 
during the 2002 Trade Fair.
The Minister of Heal th, Doctor D Parireny atwa, launched 
the PMCT communication strategy in Chivi district in June 
2003. However, this PMTCT national communication 
strategy has not been made available to PMTCT sites due 
to production and distribution constrains.
All PMTCT interventions should include a community 
education component. Before and during interventions, 
programme pi anners need to understand community norms 
and establish meaningful dialogue with community 
members. In this way culturally appropriate and varied 
interventions can be designed that meet the needs of 
beneficiaries living in diverse situations.5 
Group information about PM TCT to pregnant women 
attending antenatal care.
This information is given to all women attending antenatal 
care, and to all attendees at any health facility (including 
men). Topics covered include:
1. General information about HIV transmission and 
prevention.
2. Specific information on PMTCT interventions that 
are locally available.
3. Issues of HIV voluntary testing and confidentiality.
4. Information about nevirapine administration.2
To aid verbal communication on PMTCT, print or 
electronic information is needed for reinforcement. In 
those sites where one finds print or electronic information, 
the handouts are either too few to be distributed or the 
language is not appropriate to the local community. 
Voluntary counselling to willing mothers (pre and post 
counselling).
The World Health Organization defines voluntary 
counselling and testing (VCT) as a confidential dialogue
between a client and a care provider aimed at enabling the 
client to cope with stress and take personal decisions 
related to HIV.7 In the sites offering PMTCT services, a 
total of 1 119 health workers were trained in PMTCT.4
However, most of these health workers were not midwives 
and they do not work in the antenatal, delivery or postnatal 
departments. Therefore, they do not interact with pregnant 
women to offer them counselling. With the staff attrition 
rate in Zimbabwe today, the few that are directly involved 
with pregnant women, are so overloaded with work that 
time to give quality VCT is not available. In some sites 
where donors have put in place extra staff for VCT,4 they 
are then left alone to cover the many women needing 
counselling. Thus they experience stress and bum out quickly.
The infrastructures too are another constraint for VCT 
activities in most sites offering PMTCT as there are no 
adequate private rooms set aside for counselling. Hence 
counselling either takes place in offices, side wards, 
storerooms, or any space available. This situation, affects 
the ethical issues of client comfort, privacy and 
confidentiality.
In one local town, Kapnek Charitable Trust funded the 
construction of private rooms for counselling at Vengere 
Clinic and at Rusape General Hospital.
Conducting H IV  rapid testing.
Due to the unavailability o f laboratory scientists in 
many sites offering PMCT services, the Secretary for 
Health together with the Health Professions Council in 
Zimbabwe and the Medical Laboratory and Clinical 
Scientists Council of Zimbabwe gave an exception for 
nurses to be trained in HIV rapid testing. To legalize the 
decision, the Health Professions act (Chapter 27:29) had to 
be amended. A general notice of 2003 of the act then 
included clauses to accommodate training of Nurse 
Practitioners in rapid HIV testing for the prevention of 
parent to child transmission of HIV and voluntary 
counselling and testing programme.8
In the PMTCT programme, the Centre for Disease Control 
(CDC) is the sole sponsor of HIV rapid testing kits in 
Zimbabwe. The nurses trained in HIV rapid testing are 
using combinations of Determine, Oraquick, Unigold and 
Virocheck rapid testing kits. CDC has contracted Geddes 
Pharmaceuticals to be responsible for the distribution of 
the HIV rapid testing kits.
The challenges facing availability of the HIV rapid 
testing kits at site level and the testing itself are.
1. All orders for the kits should pass through the AIDS 
and TB unit for authorization before they are posted 
to CDC and Geddes for processing. The time lapse in 
this logistical process delays availability of the kits.
2. Kits should either be collected from Geddes by 
individual PMTCT sites or Swift transport company 
could distributes them to the sites. Due to gross 
shortage of transport and fuel, most sites arc not able 
to collect their kits. Some sites do nbfhave paid up 
Swift accounts hence the company cannot transport 
their kits. Due to their geographical position, Swift 
cannot reach some PMTCT sites.
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3. While some nurses have completed the theoretical/ 
training in HIV rapid testing, the majority of them/ 
have not yet completed their practicals. Hence 
certification of these nurses is still pending (as required 
by the Medical Laboratory and Clinical Scientists 
Council before they start testing).
4. While the Medical Laboratory and Clinical Scientists 
Council requires that the nurses pay some registration 
fee and annual subscription fee  for practicing in HIV 
rapid testing, the nurses feel that this extra demand on 
their hard earned cash is not necessary as they are 
already subscribing to the Nursing Council (after all 
rapid HIV testing is not their core business).
5. Since HIV testing is such a sensitive issue, quality 
control mechanisms for the nurses doing HIV rapid 
testing have not yet been fully developed.
6. Support and supervision of these nurses remains a 
constraint, due to lack of transport, fuel and cash for 
travel and subsistence claims for the managers.
Administration o f  nevirapine to HIVpositive women and 
to the HTV exposed baby.
Studies have shown that when giving the mother and 
baby antiretroviral(ARVs) drugs nevirapine is the most 
cost effective and effective way of reducing HIV 
transmission to babies. In developed countries, ARVs are 
taken during pregnancy, delivery and breastfeeding. 
Through use of ARVs combined with elective Caesarean 
section and replacement feeding from birth the rates of 
HIV transmission to babies have been reduced to less than 
2% in these countries.5
The AIDS Clinical Trial Group (ACTG) protocol 076 
conducted in France and USA was the first trial to show 
evidence that a long course of zidovudine could reduce 
mother to child transmission of HIV. The intervention 
reduced transmission of HIV from 26% to 8%.12 A cost 
benefit analysis of this zidovudine regime showed that it 
was not economically viable and applicable in resource 
poor countries.1314
The Thailand clinical trial using short course Zidovudine 
revealed a 50% reduction in HIV transmission,15 Though 
this shortened course was cheaper, because of the 
breastfeeding practices in African countries it was found to 
be unsuitable.16
The Uganda clinical trail (HIVNET 012) which involved 
administration of 200mg of nevirapine to the mother 
during labour and 2mg/kg to the baby within 72 hours of 
birth was found to be effective and economically viable for 
resource-poor countries. In the study, it was found that at' 
14 to 16 weeks of age, the transmission rate was 13.1% in 
the nevirapine group compared to 25.1% in the zidovudine 
group.17'19 This is the regime that is being used in the 
Zimbabwe PMTCT programme.
If an HIV positive woman reaches 28 weeks gestation, 
she is given nevirapine 200mg to take home. As_soon as. 
true labour starts, the woman is advised to swallow her 
nevirapine tabletjOnce an HIV exposed baby is born, he/ 
she is also given nevirapine within 72 hours of birth.4
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The logistical challenges facing distribution of HIV 
rapid testing kits also affects the distribution of nevirapine. 
However, other challenges include: 1 -
1. Disclosure issues by HIV positive women since HIV 
is highly stigmatized in Zimbabwe. HIV infected 
people experience social rejection and discrimination.7 
When an HIV positive women is given nevirapine to 
take home, she finds it hard to tell other nurses that 
she has nevirapine. If by any chance she delivers at 
home, (as was noted in the Zimbabwe Demographic 
and Health Survey (1999) that a child in a rural area 
is almost four times more likely to have been born at 
home than an urban child), she finds it hard to tell the 
traditional birth attendants that she has nevirapine td- 
take.
2. Unavailability of nevirapine syrup at rural health 
centre level. If an HIV positive women delivers at 
home, even if she has taken her nevirapine tablet, 
when she takes her child to the rural health centre, she 
is shocked to be told that her child cannot get 
nevirapine because it is not available at that level of 
the health delivery system. She then has to travel 
kilometers to the next level where nevirapine syrup is 
likely to be available (that is if that level is offering 
PMTCT services).
Follow up o f  mother and baby pairs.
Long term care of HIV exposed mothers and babies is 
ultimately expected to be offered within the Integrated 
Management of Childhood Illnesses [IMCI] programme 
which is currently being developed within Zimbabwe and 
funded by UNICEF. The currently recommended schedule 
of visits for HIV exposed infants is combined with the 
routine follow up/immunization schedule {10 days, six 
weeks, three, four, five, nine, 12,15 to 18 months 
respectively}. Follow up may be more frequent for HIV 
exposed infants if symptomatic infections are present. 
Cotrimoxazole given as a prophylactic medication can be 
life saving and prevent serious complications from 
opportunistic infections. Follow up should be linked to 
existing community-based care programmes.2
While guidelines for the follow up of mother and baby 
pairs exposed to HIV are in place, the challenge being 
experienced is to identify these mothers and babies at any 
level of the health care delivery system. The system of 
follow up of these mothers and babies is thus not well 
established.
Cotrimoxazole tablets and syrup are not always readily 
available in adequate stocks for the increasing number of 
mothers and babies. Antiretrovirafdrugs (ARVs) are also 
not yet readily available and affordable to the same mothers 
and babies.
At every visit, mothers ask health workers the famous 
question ‘Is my baby now HIV negative?’ Polymerase 
Chain Reaction (PCR) can be used to diagnose HIV 
infection in the infant from a few weeks of age. However, 
it is not currently available in Zimbabwe. In babies, ELISA 
or any HIV rapid test can be performed at any age, but these
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are inappropriate before 15 months of age.2 thus health 
workers cannot give answers to the mothers basing their 
facts on clinical evaluations.
To date there is no published record to show the proportion 
o f babies who are HIV negative after both mothers and 
babies have taken nevirapine in the PMTCT national 
expansion programme.
This information would be useful:
1. To make informed decisions on whether to continue 
the PMTCT programme using nevirapine.
.2. To m otivate com m unities to increase their 
participation in the PMTCT programme.
3. To lure more donors into funding the more complex ' 
facets of the PMTCT programme.
The challenge contributing towards lack of data that 
shows the number of babies who are-HIV negative post 
nevirapine administration, is that the PMTCT monitoring 
tools did not capture this data. The data capturing 
mechanisms in the PMTCT programme have not been 
integrated into the existing health information reporting 
system. However, it is hoped that in 2004 the revised 
PMTCT progress reports will be able to capture this data.
Since some organizations involved in the PMTCT 
programme are approaching the programme from a research 
perspective, they could be using data that shows the 
positive effects of nevirapine. The author advocates sharing 
this information with the Ministry of Health and Child 
Welfare and other stakeholders in the PMTCT programme.
Exclusive breastfeeding for four to six months with 
abrupt weaning is the standard recommendation for good 
infant feeding in PMTCT in Zimbabwe. However, though 
this practice has been promoted, it is often not practiced 
exclusively for several reasons:
• Some women go to work outside the home, hence 
they cannot exclusively breastfeed.
• Women may not get the adequate support they need 
from their families to enable them to exclusively 
breastfeed and abruptly wean their children at six 
months.
• Breast milk substitutes are not locally available in 
remote communities and are also very expensive in 
communities where they are available.5
A review of breastfeeding practices by UNICEF showed 
that in Zimbabwe, only 16% of mothers exclusively 
breastfed for three months. UNICEF concluded that in 
most developing countries where breastfeeding is the 
norm, it is mixed feeding that is practiced.20
Breastfeeding as a risk factor for HIV transmission from 
mother to child was first demonstrated as a case report 
from Australia,21 where cumulative evidence from studies 
from North America, Europe and Africa confirmed the 
finding.22'25
* Studies are still giving varying figures (ranging from 
25% to 48.7%) for mother to child transmission of HIV; 
14% to 20% being associated with breastfeeding.26'2^
The World Health Organization still recommends 
exclusive breastfeeding during the first six months of life, 
but where replacement feeding is acceptable, feasible, 
affordable, sustainable and safe, the HIV positive mother 
should avoid breastfeeding.30 
PMTCT progress.
The following activities are among the other mentioned 
PMTCT programme achievements:
1. Production of a national PMTCT training manual 
(October 2002).
2. A draft PMTCT trainer of trainers curriculum guide.
3. A draft PMTCT Logistics and Procedure Manual 
(October 2002).
4. PMTCTNational Site Protocols for Ministry of Health 
and Child Welfare Zimbabwe (February 2003).
5. A draft PMTCT National Communication package 
(launched in June 2003).
6. Draft PMTCT monitoring tools (finalized in 
November 2003).
Table I gives a summary of the PMTCT national 
expansion progress. From the registered sites, monitoring 
of the PMTCT programme showed that from January to 
December 2002, 45 690 women were eligible for 
counselling. However, 33 724 (73.8%) women were 
reported to have had pretest counselling. Of those 
counselled, 66% agreed to have an HIV test and of those 
who were tested, 22% were found to be HIV positive. 
About 35 % of those who were found to be HIV positive 
received nevirapine for PMTCT of HIV.4
Table I: PMTCT provincial progress reports 2002.
Characteristics Mac M C M E MW MN M S M ID M a s Hre B yo Chi TOT
New A N C  Counselled 6 415 4 050 2 302 2 981 987 3 790 1 091 98 2 991 4 1 2 0 4 899 33 724
Tested 5 602 3 220 1 004 805 108 1 889 845 41 1 397 3 1 7 2 3 904 2 20 79
HIV pos 1 002 587 163 284 42 '380 202 16 203 984 998 4 861
nvp mother 102 426 52 98 2 22 49 6 235 230 490 1 712
nvp baby 102 326 68 109 2 36 65 6 90 105 498 1 407
Key: Mac: Manicaland MC: M ashonaland  Central M E: M ashonaland  East MW: M ashonaland  West
MN: Matebeleland North M S: Matebeleland  South MID: M idlands Mas: M asv ingo
Hre: Harare Byo: Bulaw ayo Chi: Chitungwiza H IV  p o s:  H IV  positive
nvp: Nevirapine
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The variations in the figures presented from the provinces 
are due to:
1. Differences in the number ofPMTCT sites established 
in each province or town. (M anicaland 29, 
Mashonaland central five, Mashonaland west 30, 
Mashonaland East 13, Matebeleland North 18, 
Matebeleland South seven, Midlands 12, Masvingo 
41, Harare 11, Bulawayo seven, Chitungwizafive).10
2. The time the sites got registered and became fully 
operational (some sites in other provinces were 
established as early as February 2002 while sites in 
Masvingo were established much later).
3. Health worker perceptions, experiences, attitudes, 
commitment and motivation within each site.
4. Donor support in each province (funds for training, 
support and supervision and creation of additional 
posts for PMTCT staff were readily made available 
to some privileged districts like Nyanga, Rusape, 
Seke, Mudzi, Chivhu, Chinhoyi, Banket, Kadoma 
and Kariba).
5. Erratic availability of nevirapine tablets and syrup 
and HIV test kits at site level.
The possible challenges as to why Harare has very few 
mothers who were counselled could firstly be that only 
four out of the 12 health facilities in the City Health 
Department were registered and operational PMTCT sites, 
and secondly that data on PMTCT activities in the private 
sector in Harare is not being captured.
The reason why Harare gave more nevirapine to mothers 
other than those found to be HIV positive in its centres 
could be that Harare receives more referrals. Some of the 
referred women could have received nevirapine during 
antenatal care in their rural centres.
In a more general analysis, the data shows a reduction in 
the numbers of women who get tested for HIV and who 
eventually take nevirapine. The author wonders whether 
firstly, male decision making processes contributed this 
reduction, and secondly, fear within women is affecting 
uptake of the PMTCT programme.
In the area of research, there was a national assessment - 
of the PMTCT national expansion programme in 2003. 
The assessment raised the following as challenges needing 
redressing: _  • '
1. Barriers to same-day provision of rapid HIV test 
results (namely staffing, training and procedural 
issues).
2. Minimal mother infant follow up.
3. Standardization of staffing for both counselling and 
PMTCT management.
4. Erratic site access to nevirapine and HIV test kits.
5. Lack of space for counselling.
Major challenges to the PMTCT progress in Zimbabwe 
have been noted to include:
• Manpower and transport shortages.
• High staff turnover.
• Limited male participation.
• Use of draft monitoring and evaluation tools for 
PMTCT.
• Lack of operational research to guide some decisions.4
Conclusion
While the Zimbabwe PMTCT National Expansion 
Programme has been rolled out, challenges and 
recommendations highlighted in the PMTCT national 
assessment (2003) need to be reviewed and informed 
decisions made so that the biggest question ‘is.my child 
now HIV negative’ can be answered.
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